Characterization of Abdomino-pelvic Lesions by 18Fluorine- Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography

NCT ID: NCT07127627

Last Updated: 2025-08-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

79 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-31

Study Completion Date

2028-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to identify and characterize lesions in the abdominopelvic region detected by 18fluorine- fluorodeoxyglucose (FDG) positron Emission Tomography combined Computed Tomography (PET/CT) scan, including determining their malignant or benign nature, and to determine the extent of disease to facilitate proper management

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

positron Emission Tomography combined Computed Tomography is a hybrid imaging that provides both anatomical and functional data that helps to differentiate between benign and malignant diseases. \[18F\]FDG is taken up by both normal cells utilizing glucose like (kidneys, ureters and urinary bladder due to urinary excretion, Variable degrees of uptake can also seen in the liver, spleen, bone marrow, bowel, testes and uterus) .and also the tumor cells which usually have a high glucose demand. This uptake is mediated by the cell surface carrier molecules designated as glucose transporters (GLUT) and can be measured with the semi quantitative index called standardized uptake values (SUV) Cancer cells divide rapidly and have greater metabolic rates. Through the upregulation of glucose transport proteins on the cell membrane, cancer cells exhibit enhanced glucose uptake . Studies have demonstrated that SUV of 2.5 can differentiate malignant versus benign tissues , thus, Proper characterization of abdomino-pelvic lesions will lead to improve chances for successful management and treatment.

Multiple studies have shown that Dual-time point (DTP) 18F-FDG PET/CT may provide more help in the differentiation of malignant lesions from benign ones.as Dual-Time-Point PET/CT involves two scans, one early and one delayed, allowing for the assessment of FDG uptake kinetics, malignant tumors tend to show increased FDG uptake over time, indicating higher glucose metabolism. But benign Lesions or those with inflammatory processes may show a decrease or no significant change in FDG uptake over time.

FDG activity in urine interferes with tumor activity. Therefore, the value of FDG PET has only a limited role in detecting tumors in the bladder wall and urinary tract, Thus several methods have been investigated and tested to reduce urine FDG activity: catheterization, dual-phase imaging, early PET images, late PET images after voiding, oral hydration, and forced diuresis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PET/CT

positron emission tomography/computed tomography

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* patients underwent recent abdominal or pelvic surgery.
* patients with blood glucose level ˃200 mg/dL
* Pregnancy
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Salma A samy

assistant lecturer of nuclear medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

salma A samy, ass. lecturer

Role: CONTACT

01069720261

waleed A diab, ass. prof

Role: CONTACT

01004242213

References

Explore related publications, articles, or registry entries linked to this study.

Bouchelouche K. PET/CT in Bladder Cancer: An Update. Semin Nucl Med. 2022 Jul;52(4):475-485. doi: 10.1053/j.semnuclmed.2021.12.004. Epub 2022 Jan 5.

Reference Type BACKGROUND
PMID: 34996595 (View on PubMed)

Khandelwal Y, Singh Parihar A, Sistani G, Ramirez-Fort MK, Zukotynski K, Subramaniam RM. Role of PET/Computed Tomography in Gastric and Colorectal Malignancies. PET Clin. 2024 Apr;19(2):177-186. doi: 10.1016/j.cpet.2023.12.004. Epub 2024 Jan 9.

Reference Type BACKGROUND
PMID: 38199915 (View on PubMed)

Wang J, Liu X. Medical image recognition and segmentation of pathological slices of gastric cancer based on Deeplab v3+ neural network. Comput Methods Programs Biomed. 2021 Aug;207:106210. doi: 10.1016/j.cmpb.2021.106210. Epub 2021 May 29.

Reference Type BACKGROUND
PMID: 34130088 (View on PubMed)

Sartin SL, Shetty DR, Strange CD, Gayer G, Ahuja J, Agrawal R, Truong MT. Pitfalls in Positron Emission Tomography/Computed Tomography in the Thorax and Abdomen. Semin Ultrasound CT MR. 2024 Dec;45(6):488-495. doi: 10.1053/j.sult.2024.07.012. Epub 2024 Jul 26.

Reference Type BACKGROUND
PMID: 39069275 (View on PubMed)

Cao Y, Zhou K, Diao W, Long X, Tian F, Su M, Jia Z. Age-related changes of standardized uptake values in the blood pool and liver: a decade-long retrospective study of the outcomes of 2,526 subjects. Quant Imaging Med Surg. 2021 Jan;11(1):95-106. doi: 10.21037/qims-20-35.

Reference Type BACKGROUND
PMID: 33392014 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

characterization by PET/CT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.